神奇制药
(600613)
| 流通市值：36.09亿 | | | 总市值：40.22亿 |
| 流通股本：4.79亿 | | | 总股本：5.34亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,563,273,519.07 | 1,110,366,035.45 | 574,528,830.84 | 2,340,945,518 |
| 营业收入 | 1,563,273,519.07 | 1,110,366,035.45 | 574,528,830.84 | 2,340,945,518 |
| 二、营业总成本 | 1,481,112,830.96 | 1,052,894,598.73 | 543,620,372.68 | 2,246,305,246.56 |
| 营业成本 | 799,209,934.66 | 584,204,305.3 | 291,963,969.03 | 1,172,062,315.51 |
| 税金及附加 | 21,906,440.35 | 14,723,863.51 | 9,990,823.78 | 29,072,794.64 |
| 销售费用 | 559,647,311.54 | 387,480,185.73 | 212,443,264.19 | 909,409,176.86 |
| 管理费用 | 66,570,448.65 | 41,077,880.85 | 18,615,043.03 | 92,534,824.12 |
| 研发费用 | 31,895,111.13 | 25,115,733.73 | 8,960,100.75 | 32,304,982.17 |
| 财务费用 | 1,883,584.63 | 292,629.61 | 1,647,171.9 | 10,921,153.26 |
| 其中:利息费用 | 8,766,698.93 | 5,652,652.63 | 3,016,207.09 | 14,763,810.95 |
| 其中:利息收入 | 6,927,613.62 | 6,430,701.71 | 1,461,637.87 | 5,158,763.57 |
| 加:公允价值变动收益 | -306,263.98 | 45,081.88 | -7,877.97 | 897,679.62 |
| 加:投资收益 | 797,136.97 | - | - | 810,174.97 |
| 资产处置收益 | 159,663.56 | 151,917.7 | 151,917.7 | 268,660.79 |
| 资产减值损失(新) | -963,504.41 | -1,321,213.57 | - | -72,412,600.81 |
| 信用减值损失(新) | -11,418,386.47 | -11,481,576.47 | 90,360 | 47,685,053.3 |
| 其他收益 | 3,892,837.07 | 3,037,469.26 | 603,356.71 | 10,949,955.1 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 74,322,170.85 | 47,903,115.52 | 31,746,214.6 | 82,839,194.41 |
| 加:营业外收入 | 644,750.04 | 573,158.31 | 28,453.17 | 931,933.34 |
| 减:营业外支出 | 2,755,865.41 | 1,158,096.5 | 389,838.65 | 363,161.24 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 72,211,055.48 | 47,318,177.33 | 31,384,829.12 | 83,407,966.51 |
| 减:所得税费用 | 13,396,898.52 | 8,427,166.5 | 6,261,692.49 | 25,148,750.35 |
| 六、净利润 | 58,814,156.96 | 38,891,010.83 | 25,123,136.63 | 58,259,216.16 |
| 持续经营净利润 | 58,814,156.96 | 38,891,010.83 | 25,123,136.63 | 58,259,216.16 |
| 归属于母公司股东的净利润 | 59,353,789.97 | 37,837,024.85 | 23,944,713.73 | 57,000,674.55 |
| 少数股东损益 | -539,633.01 | 1,053,985.98 | 1,178,422.9 | 1,258,541.61 |
| (一)基本每股收益 | 0.11 | 0.07 | 0.04 | 0.11 |
| (二)稀释每股收益 | 0.11 | 0.07 | 0.04 | 0.11 |
| 八、其他综合收益 | 13,352,966.11 | -1,324,852.13 | 223,699.68 | 4,813,822.44 |
| 归属于母公司股东的其他综合收益 | 13,352,966.11 | -1,324,852.13 | 223,699.68 | 4,813,822.44 |
| 九、综合收益总额 | 72,167,123.07 | 37,566,158.7 | 25,346,836.31 | 63,073,038.6 |
| 归属于母公司股东的综合收益总额 | 72,706,756.08 | 36,512,172.72 | 24,168,413.41 | 61,814,496.99 |
| 归属于少数股东的综合收益总额 | -539,633.01 | 1,053,985.98 | 1,178,422.9 | 1,258,541.61 |
| 公告日期 | 2024-10-31 | 2024-08-31 | 2024-04-30 | 2024-04-30 |
| 审计意见(境内) | | | | 标准无保留意见 |